{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:03:05Z","timestamp":1788951785683,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000969","name":"American Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015087","name":"Markey Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canlet.2024.217281","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T20:53:20Z","timestamp":1728075200000},"page":"217281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer"],"prefix":"10.1016","volume":"605","author":[{"given":"Daniel R.","family":"Plaugher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery R.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Gosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave-Preston","family":"Esoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassandra J.","family":"Naughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-5043","authenticated-orcid":false,"given":"Christine F.","family":"Brainson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217281_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2024.217281_bib2","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1016\/j.cllc.2021.03.007","article-title":"Description of a lung cancer hotspot: disparities in lung cancer histology, incidence, and survival in Kentucky and appalachian Kentucky","volume":"22","author":"Brainson","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217281_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217281_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.217281_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ccell.2023.03.003","article-title":"Adoptive cell transfer immunotherapy for patients with solid epithelial cancers","volume":"41","author":"Rosenberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217281_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217281_bib9","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-2005-871990","article-title":"Factors predicting response to EGFR tyrosine kinase inhibitors","volume":"26","author":"Engelman","year":"2005","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2024.217281_bib11","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-14-2748","article-title":"Lung cancer in the era of precision medicine","volume":"21","author":"Politi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cllc.2018.02.004","article-title":"Clinicopathologic features and immune microenvironment of non-small-cell lung cancer with primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"19","author":"Takashima","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217281_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217281_bib21","series-title":"Immunotherapy for Advanced Non\u2013small Cell Lung Cancer: A Decade of Progress","first-page":"e105","author":"Shields","year":"2021"},{"key":"10.1016\/j.canlet.2024.217281_bib22","doi-asserted-by":"crossref","first-page":"e3733","DOI":"10.3390\/cancers15143733","article-title":"Cellular therapy for lung cancer: focusing on chimeric antigen receptor T (CAR T) cells and tumor-infiltrating lymphocyte (TIL) therapy","volume":"15","author":"Katiyar","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217281_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib24","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.217281_bib27","doi-asserted-by":"crossref","first-page":"10041","DOI":"10.1007\/s00432-023-04924-7","article-title":"TP53 or CDKN2A\/B covariation in ALK\/RET\/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis","volume":"149","author":"Jiang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib28","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immuno. Ther. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.217281_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2024.217281_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib39","series-title":"The Immune System, (Garland Science)","author":"Parham","year":"2015"},{"key":"10.1016\/j.canlet.2024.217281_bib40","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib41","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.217281_bib42","first-page":"1067","article-title":"In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2","volume":"79","author":"Spiess","year":"1987","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.217281_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2024.217281_bib44","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.4049\/jimmunol.142.10.3714","article-title":"Tumor-specific cytolysis by lymphocytes infiltrating human melanomas","volume":"142","author":"Topalian","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1753-4887.1989.tb02747.x","article-title":"Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858","volume":"47","author":"Virchow","year":"1989","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.canlet.2024.217281_bib46","first-page":"385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib48","article-title":"First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217281_bib49","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217281_bib50","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib53","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri.2017.146","article-title":"Epigenetic control of CD8+ T cell differentiation","volume":"18","author":"Henning","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.it.2006.03.007","article-title":"T-cell homing specificity and plasticity: new concepts and future challenges","volume":"27","author":"Mora","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/BST20150254","article-title":"Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells","volume":"44","author":"Ager","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.canlet.2024.217281_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057386","article-title":"The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity","volume":"5","author":"Forget","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.217281_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.it.2014.02.003","article-title":"Reprogramming antitumor immunity","volume":"35","author":"Crompton","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib59","doi-asserted-by":"crossref","first-page":"e4160","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217281_bib60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217281_bib61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor\u2013engineered T cells targeting common p53 neoantigens in human solid tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217281_bib62","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1007\/s00262-023-03476-6","article-title":"Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens","volume":"72","author":"Parikh","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib63","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CJI.0b013e31819c8bda","article-title":"Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients","volume":"32","author":"Besser","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib66","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","article-title":"Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy","volume":"31","author":"Tran","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.217281_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217281_bib69","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.217281_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2017.03.012","article-title":"Polycomb repressive complex 2-mediated chromatin repression guides effector CD8(+) T cell terminal differentiation and loss of multipotency","volume":"46","author":"Gray","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217281_bib71","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1186\/s40779-023-00496-2","article-title":"Targeting the epigenome to reinvigorate T cells for cancer immunotherapy","volume":"10","author":"Xiong","year":"2023","journal-title":"Milit. Med. Res."},{"key":"10.1016\/j.canlet.2024.217281_bib72","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217281_bib73","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217281_bib74","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2767-9764.CRC-23-0399","article-title":"EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas","volume":"4","author":"DuCote","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2024.217281_bib75","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217281_bib76","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti\u2013PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib77","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41467-017-02187-8","article-title":"Ezh2 phosphorylation state determines its capacity to maintain CD8(+) T memory precursors for antitumor immunity","volume":"8","author":"He","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217281_bib78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00199837","article-title":"Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer","volume":"24","author":"Kradin","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib79","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.217281_bib80","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","article-title":"A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma","volume":"78","author":"Ratto","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib81","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J. Immuno. Ther. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib82","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib83","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.217281_bib84","first-page":"A873","article-title":"776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144\u201301 study","volume":"11","author":"Medina","year":"2023","journal-title":"J. Immuno. Ther. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib85","first-page":"100589","article-title":"Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144-01 study","volume":"20","author":"Wermke","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217281_bib86","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.217281_bib87","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","article-title":"Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients","volume":"67","author":"Ben-Avi","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.217281_bib88","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217281_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153053","article-title":"Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy","volume":"11","author":"Kodumudi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.217281_bib90","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J. Immuno. Ther. Cancer"},{"key":"10.1016\/j.canlet.2024.217281_bib91","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T15:44:21Z","timestamp":1731253461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524006761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":91,"alternative-id":["S0304383524006761"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217281","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217281"}}